For the first time, the effects of combinations of trimethoprim and a fluoroquinolone (ciprofloxacin) against gram-positive and gram-negative bacterial isolates were evaluated in vitro. Synergism was found in 31 % (fractional inhibitory concentration, FIC) and 33 % (fractional bactericidal concentration, FBC) of 121 clinical isolates of various bacterial strains, most often inEscherichia coli, staphylococci, and enterococci. Antagonism occurred in 1 % (FIC) and 3 % (FBC). The combination of trimethoprim and ciprofloxacin merits further evaluation for potential usefulness as a clinical regimen.
Internal Medicine Bacterial Strain Inhibitory Concentration Clinical Isolate Fluoroquinolone
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Heikkilä E, Renkonen O-V, Sunila R, Uurasmaa P, Huovinen P: The emergence and mechanisms of trimethoprim resistance inEscherichia coli isolated in outpatients in Finland. Journal of Antimicrobial Chemotherapy 1990, 25: 275–283.PubMedGoogle Scholar
Hooper DC, Wolfson JS, Souza KS, Ng EY, McHugh GL, Swartz MN: Mechanisms of quinolone resistance inEscherichia coli: characterization ofnfxB andcfxB, two mutant resistant loci decreasing norfloxacin accumulation. Antimicrobial Agents and Chemotherapy 1989, 33: 283–290.PubMedGoogle Scholar
Kotilainen P, Nikoskelainen J, Huovinen P: Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. Journal of Infectious Diseases 1990, 161: 41–44.PubMedGoogle Scholar
Schaefler S: Methicillin-resistant strains ofStaphylococcus aureus resistant to quinolones. Antimicrobial Agents and Chemotherapy 1989, 27: 335–336.Google Scholar
Shalit I, Berger SA, Gorea A, Frimerman H: Wide-spread quinolone resistance among methicillin-resistantStaphylococcus aureus isolates in a general hospital. Antimicrobial Agents and Chemotherapy 1989, 33: 593–594.PubMedGoogle Scholar
Hallander HO, Dornbusch K, Gezelius L, Jacobson K, Karlsson I: Synergism between aminoglycosides and cephalosporins with antipseudomonal activity. Antimicrobial Agents and Chemotherapy 1982, 22: 743–752.PubMedGoogle Scholar
Wolfson JS, Hooper DC, Ng EY, Souza KS, McHugh GL, Swartz MN: Antagonism of wild-type and resistantEscherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers. Antimicrobial Agents and Chemotherapy 1987, 31: 1861–1863.PubMedGoogle Scholar
Gellert M, Mizuuchi K, O'Dea MH, Itoh T, Tomizawa JI: Nalidixic acid resistance. A second genetic character involved in DNA gyrase activity. Proceedings of the National Academy of Sciences of the USA 1977, 74: 4772–4776.PubMedGoogle Scholar
Eliopoulos GM, Eliopoulos CT: Ciprofloxacin in combination with other antimicrobials. American Journal of Medicine 1989, 87, Supplement 5A: 17–22.CrossRefGoogle Scholar
Bertolini A, Castelli M, Genedani S, Garuti M: Trimethoprim enhances the antibacterial activity of nalidixic acid and oxolinic acid and delays the emergence of resistance. Experientia 1980, 36: 243–244.CrossRefPubMedGoogle Scholar
Genedani S, Castelli M, Foresta P, Bertolini A: Oxolinic acid — trimethoprim combination: effects on DNA synthesis and on viability ofEscherichia coli. Chemotherapy 1983, 29: 24–27.PubMedGoogle Scholar